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ception (Harter total scale: p  ! 0.01), and bodily attitude 
(Baardman: p  ! 0.05) was signifi cantly less positive than 
for their normal Dutch peers, we found no evidence of 
depression. TS women rated their family functioning 
higher than their Dutch peers (p  ! 0.0001), and had a 
slightly different coping pattern. These results show that 
even after reaching a height in most cases within the nor-
mal range and puberty induction at a pubertal age, some 
women with TS still experience psychosocial problems. 
It is likely, however, that GH and estrogen treatment im-
proved psychosocial functioning. Long-term follow-up of 
these GH-treated patients will allow an evaluation of their 
life achievements. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 The most frequent clinical characteristics of Turner 
syndrome (TS) are short stature and the absence of spon-
taneous pubertal development. In most countries it is 
common practice to treat short stature in TS with GH 
treatment in a supraphysiological dosage. In addition, es-
trogens are given to induce puberty at an age as close to 
normal puberty as possible. This approach has been 
shown to increase and even normalize height in child-
hood, adolescence, and adulthood in TS  [1–5] . Little data 
is available, however, on the effect of this treatment strat-
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 Abstract 
 It is common practice in the case of Turner syndrome (TS) 
to treat short stature with GH treatment and to induce 
puberty with estrogens at an age as close to normal pu-
berty as possible. This approach in most cases leads to a 
height in the normal range in childhood, adolescence, 
and adulthood in TS. Little data is available, however, on 
its effect on psychosocial functioning. In the present 
study, we evaluated psychosocial functioning in a group 
of 50 women with TS, after reaching fi nal height in two 
multicenter GH trials. Thirty-six girls participated in a ran-
domized dose-response study from mean (SEM) age 6.8 
(0.4) years, and 14 girls participated in a frequency-re-
sponse study from age 13.2 (0.4) years. After discontinu-
ation of long-term GH treatment, these 50 girls were eval-
uated for psychosocial functioning at a mean age of 18.8 
(0.3) years. GH was given in a dosage of 4 IU/m 2 /day 
(  0.045 mg/kg/day), 6 IU/m 2 /day, or 8 IU/m 2 /day. After a 
mean GH treatment duration of 7.1 (0.4) years, mean fi nal 
height (ref. normal girls) was FH1.2 (0.2) SD score. Behav-
ioral problem scores (Achenbach) of the TS women were 
comparable to normal Dutch peers. Although self-per-
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egy on psychosocial functioning. Untreated girls with TS 
have been described as being more immature, having a 
lower self-esteem, poor concentration, and being hyper-
active  [6, 7] . 
 In the present study, we evaluated psychosocial func-
tioning in a group of 50 women with TS, after reaching 
ﬁ nal height in two multicenter GH trials. 
 Methods 
 GH Group 
 All women who had participated in two GH trials (see below), 
had discontinued GH treatment for more than 6 months, and were 
able to ﬁ ll in the questionnaires, were asked to participate in the 
psychosocial evaluation. Fifty women agreed to participate (re-
sponse rate 50/69: 72%). Nineteen girls did not participate either 
because of practical reasons or because of losing interest in par-
ticipating in a study. 
 Both GH trials evaluated the effect of GH on long-term growth 
and ultimately on ﬁ nal height (FH). At time of the psychosocial 
evaluation, all participants were prescribed hormone replacement 
therapy in an adult dose. 
 Dose-Response GH Trial 
 Sixty-eight previously untreated Dutch girls with TS, aged be-
tween 2 and 11 years, were enrolled in an open randomized multi-
center GH dose-response study (DRS). Biosynthetic GH (r-hGH 
Norditropin ® , Novo Nordisk A/S, Denmark) was given subcutane-
ously once daily in a dosage of 4, 6, or 8 IU GH/m 2  body surface 
area/day (  0.045–0.09 mg/kg/day). Puberty was induced at age 12 
years (study design as described previously  [5] ). Six girls dropped 
out of the study and were lost to follow-up. Six girls had not discon-
tinued GH treatment for more than 6 months and 4 girls were un-
able to ﬁ ll in the questionnaires due to mental retardation, leaving 
52 girls able to participate in the psychosocial evaluation. 
 Frequency-Response GH Trial 
 Nineteen previously untreated Dutch girls aged 11 years or old-
er, with TS, were enrolled in an open randomized multicenter GH 
frequency-response study (FRS). Biosynthetic GH was given sub-
cutaneously once or twice daily in a total dosage of 6 IU GH/m 2 /
day. Puberty was induced at start of trial (study design as described 
previously  [1] ). Two girls were unable to ﬁ ll in the questionnaires 
due to mental retardation, leaving 17 girls able to participate in the 
psychosocial evaluation. 
 The GH trials and the psychological evaluation were approved 
by the Ethics Committees of the participating centers in the Neth-
erlands. Written informed consent was obtained from the parents 
or custodians of each child. 
 Normal Population Sample 
 From a randomly selected population sample from three mu-
nicipalities in the Netherlands (n = 600, response rate 56%), only 
the females were selected for comparison (n = 359)  [8] . 
 Psychosocial Evaluation 
 In the GH group a psychosocial evaluation was performed after 
GH treatment had been discontinued for at least 6 months and 
(near) FH had been reached. Questionnaires for the GH trial groups 
and the population sample were sent by post. 
 General Information.  Data on occupational and educational 
levels were provided by both parents and adolescents. Parental oc-
cupational level (SES) ranged from 1 (lower occupation) to 3 (high-
er occupation). When both parents were employed the highest of 
both SES levels was used. For unemployment the lowest SES was 
used  [9] . 
 Behavioral Problems (YSR/YASR) . Behavioral problems were 
measured by 3-point scale standardized questionnaires from 
Achenbach, translated and validated in the Dutch language  [8, 10, 
11] . For girls aged between 12 and 18 years, the 119-item Youth 
Self-Report (YSR; ﬁ lled in by child)  [12, 13] was used. For girls 
aged 18 years and older, the 127-item Young Adult Self-Report 
(YASR; ﬁ lled in by adolescent) was used  [14] . As both question-
naires were constructed in a similar way, results from three scales 
could be combined for analysis (Internalizing, Externalizing, and 
Total Problem score). To allow combination of test scales (YSR/
YASR), z-scores were constructed using the Population sample 
data as reference  [8] . A higher test z-score indicated more problem 
behavior. 
 Self-Perception (HSPP). The inventory, called in Dutch ‘Hoe 
ben ik’ and in English ‘Harter Self Perception Proﬁ le’, was designed 
by Harter to describe sense of self-worth and capability in several 
areas, using 4-point scales.  [15, 16] . In the evaluation the 45-item 
adolescent-version (HSPP-a) was used. Ten scales (Scholastic com-
petence, Social acceptance, Athletic competence, Physical appear-
ance, Behavioral conduct, Global self-worth, Romantic appeal, 
Close friendship, Job competence, and Total HSP score) were used 
for analysis (median   = 0.76). A higher test score indicated a more 
favorable self-perception. 
 Child Depression Inventory (CDI).  The American Child Depres-
sion Inventory was designed to measure depressive thoughts and 
feelings in a child population and was designed by Kovacs  [17] . 
Factor analysis of the Dutch version of the 27-item (3-point scales) 
‘Gevoelens en Gedachten vragenlijst’ produced one scale, the ‘To-
tal depression scale score’ (  = 0.86)  [8] . A higher score indicated 
more depressive thoughts and feelings. 
 Body Attitude Scale (BAS).  The Dutch questionnaire ‘Lichaams-
belevings vragenlijst’ is a 45-item questionnaire and uses a 5-point 
Likert scale to assess bodily attitude. It has been constructed and 
validated by Baardman et al.  [18] . In an adolescent population, 
three scales could be distinguished by factor analysis: ‘Appraisal’ 
(  = 0.94; e.g. ‘Are you satisﬁ ed with the way your body looks?’), 
‘Attribution’ (  = 0.88; e.g. ‘Do you think people avoid you because 
of your appearance?’), and ‘Physical contact’ (  = 0.77; e.g. ‘In gen-
eral, how much do you like touching people?’)  [8] . High test scores 
indicated positive bodily attitudes. 
 Family Assessment Device (FAD).  This shorter 12-item version 
of the General Functioning Subscale of the McMaster Family As-
sessment Device measured overall family functioning, using a 4-
point scale. Reliability and validity were tested in the original lan-
guage  [19] and in Dutch  [20] . A higher test score indicated more 
positive family functioning. 
 Coping (UCL) . The ‘Utrecht Coping list’  [21] was designed and 
validated in Dutch  [22, 23] . The 47-item 4-point scale list was made 
to measure 7 ways of coping with stressful events: Active approach 
(e.g. ‘In general, if I have a problem I tackle the problem immedi-
ately), Reassuring thoughts (e.g. ‘In general, if I have a problem I 
encourage myself’), Expression of emotion (e.g. ‘In general, if I have 
 van Pareren/Duivenvoorden/Slijper/Koot/
Drop/de Muinck Keizer-Schrama 
 
 Horm Res 2005;63:238–244 240
a problem I show I am annoyed’), Palliative reaction (e.g. ‘In gen-
eral, if I have a problem I seek distraction from it’), Passive reac-
tional pattern (e.g. ‘In general, if I have a problem I see dark clouds’), 
Seeking social support (e.g. ‘In general, if I have a problem I share 
it with someone’), Avoiding/Anticipating (e.g. ‘In general, if I have 
a problem I leave it the way it is’) (median   = 0.69). A higher test 
score indicated the coping style was more prominent. 
 Statistical Analysis 
 All data were expressed as mean (SEM) unless otherwise speci-
ﬁ ed. Differences in SES between the Population sample and the 
GH group were analyzed by logistic regression analyses. To analyze 
differences in results between the GH group and the Population 
sample regression analyses were used, corrected for age, GH trial 
(1 dummy variable: FRS = 1) and GH dosage (2 dummy variables). 
SES (2 dummy variables) was only corrected for when signiﬁ cant. 
The effect FH, corrected FH, and the increase in height from start 
of GH treatment were estimated by the addition of FH SD score, 
corrected FH SD score and height SD score at start to the regres-
sion models, with correction for age, GH trial, and GH dosage. 
Results from the regression analyses were shown as unstandardized 
coefﬁ cients (B) with their two-tailed p values. All calculations were 
done by SPSS 9.0. A p value of 0.05 was considered signiﬁ cant for 
comparison between the GH group and the normal sample. A p 
value  ! 0.01 was considered signiﬁ cant for within GH group com-
parison because of multiple testing. 
 Results 
 Clinical data of the GH trials are shown in  table 1 for 
all women who participated in the psychosocial evalua-
tion. We found no signiﬁ cant differences in clinical data 
between TS women participating in this psychosocial 
study and TS women who did not participate. Psychoso-
cial data for the DRS and FRS were analyzed together (GH 
group). Correction for GH trial (FRS or DRS) and GH 
dosage did not have a signiﬁ cant inﬂ uence on results. 
 Social Economic Status (SES) 
 In the GH group, 35% had a low SES level, 20% an 
intermediate level, and 46% a high level. The differences 
in SES between the GH group and the Population sample 
(33/34/33%, respectively) were not signiﬁ cant. Correc-
tion for SES did not signiﬁ cantly change any of the fol-
lowing results. 
 Behavior (YSR/YASR) 
 Internalizing, Externalizing, and Total problem be-
havior SD scores were comparable to the Population sam-
ple mean ( table 2 ). 
 Self-Perception (HSPP) 
 Total HSP scores ( table 3 ) were signiﬁ cantly lower 
than the Population sample scores (B = –0.30, p  ! 0.01), 
while GH dosage had no signiﬁ cant effect. To explain this 
result, we examined the remaining scale scores, which are 
the components of the Total HSP scores. Social accep-
tance, Athletic competence, and Romantic appeal scores 
were also signiﬁ cantly lower than the Population sample 
scores (B = –0.63, p  ! 0.001, B = –0.55, p  ! 0.01, B =
–0.40, p  ! 0.05, respectively). The remaining scale scores 
were not signiﬁ cantly different to the Population sample 
scores. 
 Table 1. Mean (SEM) clinical data for the girls who participated in the psychosocial evaluation and for the 
 Population sample 
Dose-response group
(GH 4–8 IU/m2/day)
Frequency-response group
(GH 6 IU/m2/day)
Population
sample
Number of girls 36 14 359
Chronological age at start GH trial, years –6.8 (0.4)## 13.2 (0.4) –
Height SD score at start (ref. normal Dutch girls) –2.7 (0.2) –3.2 (0.3) –
Final height SD score (ref. normal Dutch girls) –1.0 (0.2)# –1.9 (0.2) –
Target height SD score –0.2 (0.2) –0.3 (0.2) –
Age start puberty (B2), years 12.7 (0.1) 13.2 (0.4) –
GH duration, years –8.5 (0.3)## –3.6 (0.2) –
Karyotype: 45,X 30 (83%) 10 (71%) –
Karyotype: other –6 (17%) –4 (29%) –
Age at psychosocial evaluation, years 18.2 (0.4)# 20.4 (0.4)** 17.1 (0.2)
GH = Growth hormone.
One-way ANOVA: ** p < 0.001; two-tailed (GH group vs. Population sample).
# p < 0.01, ## p < 0.001; two-tailed (Dose-response trial vs. Frequency-response trial).
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 Child Depression Inventory (CDI) 
 Total depression scale scores were not signiﬁ cantly dif-
ferent to the Population sample scores ( table 4 ). 
 Body Attitude Scale (BAS) 
 Attribution and Physical contact were scored slightly 
but signiﬁ cantly lower than the Population sample (B = 
–0.26, p  ! 0.05, B = –0.41, p  ! 0.05, respectively;  table 4 ). 
Appraisal scores, however, were not signiﬁ cantly differ-
ent to the Population sample scores. 
 Family Assessment Device (FAD) 
 The Total FAD scale scores were signiﬁ cantly higher 
than the Population sample scores (B = 0.77, p  ! 0.0001; 
 table 4 ). 
 Coping (UCL) 
 Compared to the Population sample scores, only the 
scale Reassuring thoughts was signiﬁ cantly higher in the 
dose-response group (B = 0.32, p  ! 0.05). Scores for the 
scales Active approach, Expression of emotion, Palliative 
reaction, Passive reactional pattern, Seeking social sup-
port, and Avoiding/Anticipating were not signiﬁ cantly 
different to the Population sample ( table 5 ). 
 Correlations between Tests 
 To assess possible relations between the results, which 
were signiﬁ cantly different from the Population sample, 
partial correlations were done, corrected for GH dosage. 
The Total HSP score was signiﬁ cantly correlated to the 
Total FAD score (r = 0.38, p = 0.01), the BAS Attribution 
score (r = 0.61, p  ! 0.001) and the BAS Physical contact 
score (r = 0.57, p  ! 0.001). No correlation was found be-
 Table 2. Mean (SEM) of the SD scores of the YSR/YASR question-
naires for self-reported behavioral problems 
GH group Population 
sample
Internalizing SD score –0.3 (0.1) 0.0 (0.1)
Externalizing SD score –0.1 (0.1) 0.0 (0.1)
Total problem behavior SD score –0.1 (0.1) 0.0 (0.1)
Regression analyses, corrected for age, GH trial, and GH dos-
age: No signiﬁ cant differences (GH group vs. Population sample).
 
 
 Table 3. Mean (SEM) of the 10 scale scores of the Harter Self-per-
ception proﬁ le 
GH group Population
sample
Scholastic competence 2.7 (0.1) 2.9 (0.0)
Social acceptance 2.5 (0.1)*** 3.0 (0.0)
Athletic competence 1.9 (0.1)** 2.5 (0.0)
Physical appearance 2.3 (0.1) 2.6 (0.0)
Job competence 3.1 (0.1) 3.2 (0.0)
Romantic appeal 2.2 (0.1)* 2.5 (0.0)
Behavioral conduct 3.2 (0.1) 3.1 (0.0)
Close friendship 3.1 (0.1) 3.3 (0.0)
Global self-worth 2.8 (0.1) 3.0 (0.0)
Total HSP 2.6 (0.1)** 2.9 (0.0)
Regression analyses, corrected for age, GH trial, and GH dos-
age: * p < 0.05, ** p < 0.01, *** p < 0.001; two-tailed (GH group 
vs. Population sample).
 
 
 Table 4. Mean (SEM) of the scores for the Child Depression Inven-
tory (CDI), the Bodily Attitude Scale (BAS), and the Family Assess-
ment Device (FAD) 
GH group Population
sample
CDI
Total depression scale 1.3 (0.0) 1.3 (0.0)
BAS
Appraisal 3.6 (0.1) 3.7 (0.0)
Attribution 4.4 (0.1)* 4.4 (0.0)
Physical contact 3.4 (0.1)* 3.5 (0.0)
FAD
Overall Family functioning 3.3 (0.1)*** 2.5 (0.0)
Regression analyses, corrected for age, GH trial, and GH dos-
age: * p < 0.05 *** p < 0.001; two-tailed (GH group vs. Population 
sample).
 
 
 Table 5. Mean (SEM) of the 7 scale scores of the Utrecht Coping 
List 
GH group Population
sample
Active approach 2.3 (0.1) 2.4 (0.0)
Reassuring thoughts 2.5 (0.1)* 2.4 (0.0)
Expression of emotion 2.0 (0.1) 2.2 (0.0)
Palliative reaction 2.4 (0.1) 2.2 (0.0)
Passive reactional pattern 1.7 (0.1) 1.7 (0.0)
Seeking social support 2.6 (0.1) 2.3 (0.0)
Avoiding/Anticipating 2.1 (0.1) 2.1 (0.0)
Regression analyses, corrected for age, GH trial, and GH dos-
age: * p < 0.05; two-tailed (GH group vs. Population sample).
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tween the Total HSP score and the UCL Reassuring 
thoughts score. Total FAD score was signiﬁ cantly corre-
lated with the BAS Physical contact score (r = 0.46, p = 
0.001), while no correlation was found between Total 
FAD score and the BAS Attribution score, or the UCL 
Reassuring thoughts score. 
 Effect of Final Height 
 FH SD score or corrected FH SD score, with or with-
out correction for height SD score at start, showed no 
signiﬁ cant effect on Behavioral SD scores, Self-percep-
tion (Total HSP) scores, Depression scores, Bodily Atti-
tude scores or Family functioning scale (FAD) scores. 
Correction for height SD score at start did not affect re-
sults. 
 Discussion 
 Our study presents psychosocial functioning results 
of women with TS after reaching FH in two GH trials. 
We measured psychosocial functioning by standardized 
questionnaires on behavioral problems, self-perception, 
depression, bodily attitude, family functioning, and cop-
ing. We show that after long-term GH treatment, behav-
ior of the TS women was comparable to normal Dutch 
peers. In contrast, we show their self-perception, and 
their attitude towards their bodies was slightly less posi-
tive than for their normal Dutch peers. We found no 
evidence of increased symptoms of depression, TS wom-
en rated their family functioning higher, and had a 
slightly different coping pattern compared to their Dutch 
peers. 
 We show that self-rated problem behavior scores did 
not signiﬁ cantly differ from normal Dutch peers. Al-
though we did not evaluate psychosocial functioning be-
fore start of GH treatment in our TS group, many studies 
have found that untreated adolescent girls with TS have 
more problem behavior than normal girls  [24, 25] . Our 
results therefore suggest an improvement in problem be-
havior, after reaching a FH within the normal range for 
most and puberty induction at a pubertal age. According 
to Ross et al.  [7] improvement in (parent-reported) be-
havioral problems could be explained by the estrogen sub-
stitution alone. In other studies, similar improvement in 
behavior can be found after several years of GH treat-
ment  [26, 27] . 
 Regarding self-perception, our results show that after 
reaching a FH, in most cases, in the normal range while 
puberty was induced at a relatively normal age (12 years 
in the majority), self-perception total score was signiﬁ -
cantly lower than in normal Dutch girls. We found that 
the TS women feel they are less socially accepted, are less 
athletic, and have a lower romantic appeal than normal 
girls. Similar ﬁ nding have been reported in untreated 
girls and women with TS  [28, 29] . Several studies, how-
ever, have shown that treatment with estrogens and/or 
GH treatment improved self-perception  [7, 25, 26] . 
Whether, in our study, scores for self-perception were 
even lower before start of GH treatment, we cannot say. 
But, even if scores had improved during the GH trials, 
they did not normalize. A possible reason why self-per-
ception remained lower than normal could be the inse-
curity brought about by having typical physical TS fea-
tures. Another reason might be the incidental observa-
tion of both parents and clinicians that some girls seem 
to lack social graces. To substantiate this observation, a 
recent study showed TS women have an impairment in 
recognizing emotions on someone’s face compared with 
normal women, possibly indicating anomalies in amyg-
dala function  [30] . Another reason why our TS group 
feels less athletic might be because they actually have a 
restriction in movement. Nijhuis-van der Sanden et al. 
 [31] found that, although TS girls move with the same 
accuracy as their normal peers, they move with a sig-
niﬁ cantly lower speed and conclude that TS girls have a 
problem in execution of movement. Due to the age of 
the participants (mean age of 18 years) the role of infer-
tility was not investigated. Based on our professional ex-
perience, infertility has a larger role on self-perception 
later in life. 
 Several studies have found evidence of depression in 
TS women who were untreated or only treated with es-
trogens  [32, 33] . In our group of TS women, after long-
term GH treatment and estrogen substitution at a puber-
tal age, the results of the questionnaire show no signiﬁ -
cant signs of depression. A previous study on adolescent 
girls with TS treated with GH (100%) and estrogen (61%) 
described severe depressive symptoms in 20%  [34] of the 
girls. The factor related to these symptoms was teasing 
by peers about their physical appearance. Rickert et al. 
 [34] , however, did not show any data on height gain or 
pubertal development during GH and estrogen treatment. 
Therefore, the discrepancy in results might be explained 
by differences in height gain or pubertal development. 
Since we found no evidence of depression, this might in-
dicate the girls suffered less from teasing as a result of ad-
equate GH and estrogen treatment. 
 Furthermore, our results show that after GH treatment 
and puberty induction TS women appraise their bodies 
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similarly to their peers. Other studies have shown that TS 
girls and women when untreated score their physical ap-
pearance signiﬁ cantly lower than their peers  [28, 35] . In-
terestingly, the TS women have a small but signiﬁ cant 
tendency to attribute problems to their appearance and 
avoid physical contact. Although our group was adequate-
ly treated with GH and estrogen, we did not treat the 
typical physical TS features, other than short stature and 
absent pubertal development. It is therefore not surprising 
that they still feel insecure about their appearance. 
 Previous studies found girls with TS are often overpro-
tected by their parents  [26] . Overprotection, however, is 
also seen in other patient groups with short stature  [36] . 
One of the reasons for parents to overprotect is lack of 
peer relations of their children. On the other hand, chil-
dren with poor peer relations rely more on family func-
tioning  [37] . Several studies describe an increase in fam-
ily functioning, parallel to an increase in self-concept and 
a decrease in behavioral problems during GH treatment 
 [25, 26] . In our study, after reaching a FH within the nor-
mal range in most cases and puberty induction at a rela-
tively normal age, we found that TS women have a better 
family functioning than peers. This might indicate that 
these TS women still lack peer relations and take refuge 
in their family as a way of coping with problems  [25] . 
Another explanation might be that as a result of past med-
ical and psychosocial problems these TS women and their 
families have faced, their families actually function better 
than peer families. Rovet et al.  [26] , in their controlled 
GH trial, found an increase in family functioning and 
explained this as a greater involvement of the parents due 
to the GH treatment. 
 Commonly, girls and women with TS are described as 
withdrawing from social interaction as a way of coping 
with problems  [25, 38] . Interestingly, we show that wom-
en with TS, after long-term GH and estrogen treatment, 
have only a slightly different coping strategy than their 
peers. They used more Reassuring thoughts to cope with 
problems, while they used strategies such as Avoiding 
problems but also Active approach and Expression of 
emotions as often as their peers. These results seem to in-
dicate that, in general, TS women, after adequate GH and 
estrogen treatment, have a ‘normal’ coping strategy. 
 When we looked at the relation between our results, 
we found that TS women, who have a good self-percep-
tion, also have a good family functioning, attribute 
problems less to their appearance and enjoy physical 
contact. These results strengthen the common sugges-
tion that these TS women rely on family functioning 
more than other women  [37] , which for them leads to a 
more favorable self-perception and bodily attitude. Pre-
vious studies have described that the TS women rely on 
their families more than other women as a way to avoid 
problematic situations  [25, 37] . In the GH group, we 
show that these women avoid problems similarly to their 
peers. 
 As mentioned before, several studies show more be-
havioral problems in untreated TS girls and a decrease in 
problems during GH treatment  [25, 26] . Similarly, for 
self-perception, an improvement has been found during 
GH and estrogen treatment  [25, 26] . Although it is there-
fore likely that in our study, GH and estrogen treatment 
has had a positive effect on psychosocial development, 
we did not ﬁ nd signiﬁ cant relationships between test 
scores and (corrected) FH or a GH dosage effect. This 
might also indicate that GH treatment did not inﬂ uence 
psychosocial functioning. Another explanation for this 
might be that the GH treatment regimen in the trials, re-
gardless of the dosage, achieved its optimal effect on psy-
chosocial functioning. Similarly, in short children born 
small for gestational age, while longitudinal results show 
a signiﬁ cant increase in psychosocial functioning during 
GH treatment, results did not differ between GH dosage 
groups  [39] . In the present study, however, we are unable 
to show the extent of the effect of GH treatment, as we 
have no psychosocial data of start of the GH trials. 
 In conclusion, after long-term GH treatment, behavior 
of the TS women was comparable to normal Dutch peers. 
Although their perception of themselves and their atti-
tude towards their own bodies was slightly less positive 
than for their normal Dutch peers, we found no evidence 
of depression. In addition, TS women rated their family 
functioning higher, and had a coping pattern very similar 
to their Dutch peers. TS women with a more positive self-
perception also had a better attitude towards their bodies 
and had a better functioning family. These results show 
that even after reaching a height within the normal range 
and puberty induction at a pubertal age, some women 
with TS still experience psychosocial problems. It is, how-
ever, likely that GH and estrogen treatment improved 
psychosocial functioning. Long-term follow-up of these 
GH-treated patients will allow an evaluation of their life 
achievements. 
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